Heron Therapeutics Stock News

Pacira price target raised to $60 from $54 at Piper Sandler Piper Sandler PCRX HRTX

Heron Therapeutics weakness a buying opportunity, says Cowen Cowen HRTX

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 19) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Akebia

After Cantor Fitzgerald and Stifel Nicolaus gave Heron Therapeutics (NASDAQ: HRTX) a Buy rating last month, the company received another Buy, this time

After Cantor Fitzgerald and Stifel Nicolaus gave Heron Therapeutics (NASDAQ: HRTX) a Buy rating last month, the company received another

Healthcare stocks have a reputation of keeping investors on their toes. The possibility of surging price action, or conversely, earth shattering drops is very real, but these movements can come and go

Healthcare stocks have a reputation of keeping investors on their toes. The possibility of surging price action, or conversely, earth shattering drops is

Stifel Nicolaus analyst Derek Archila maintained a Buy rating on Heron Therapeutics (HRTX) today. The company's shares closed last Monday at $21.66.

Stifel Nicolaus analyst Derek Archila maintained a Buy rating on Heron Therapeutics (HRTX – Research Report) today. The company’s shares

Russell Investments Group Ltd. raised its holdings in Heron Therapeutics Inc (NASDAQ:HRTX) by 63.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commiss

Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most importan